Literature DB >> 33084533

Elevated serum calprotectin as an inflammatory marker in obstructive sleep apnea.

Nurcan Yurtsever Kum1, Rauf Oguzhan Kum1, Tuba Candar2, Deniz Baklaci3, Ismail Guler4, Ihsan Kuzucu5, Kursat Murat Ozcan1, Muge Ozcan1, Huseyin Dere1,6.   

Abstract

OBJECTIVE: To investigate the serum calprotectin (SCal) levels and neutrophil/lymphocyte ratio (NLR) values in patients with obstructive sleep apnea (OSA).
METHODS: Sixty-seven OSA patients and 46 healthy volunteers without any sleep disorders were included in the study. The patient group was divided into three subgroups according to the severity of OSA. The SCal levels and NLR values were compared among subgroups and between the experimental and control groups.
RESULTS: The mean SCal level and NLR value were higher in the study group than in the control group (p = 0.002 and p = 0.001, respectively). The SCal levels were significantly higher in patients with severe OSA than in those with moderate and mild OSA (p = 0.004 and p = 0.001, respectively). DISCUSSION: Unlike NLR, the SCal level may inform the severity of OSA and could be used as an indicator for OSA.

Entities:  

Keywords:  Calprotectin; inflammation; neutrophil/lymphocyte ratio; obstructive sleep apnea

Year:  2020        PMID: 33084533     DOI: 10.1080/08869634.2020.1839721

Source DB:  PubMed          Journal:  Cranio        ISSN: 0886-9634            Impact factor:   2.020


  2 in total

1.  Serum calprotectin as a novel biomarker for severity of COVID-19 disease.

Authors:  Tezcan Kaya; Selçuk Yaylacı; Ahmet Nalbant; İlhan Yıldırım; Havva Kocayiğit; Erdem Çokluk; Mehmet Ramazan Şekeroğlu; Mehmet Köroğlu; Ertuğrul Güçlü
Journal:  Ir J Med Sci       Date:  2021-02-27       Impact factor: 1.568

Review 2.  Calprotectin in Lung Diseases.

Authors:  Ourania S Kotsiou; Dimitrios Papagiannis; Rodanthi Papadopoulou; Konstantinos I Gourgoulianis
Journal:  Int J Mol Sci       Date:  2021-02-08       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.